Drug Profile
Research programme: rheumatoid arthritis immunotherapy - NIOX
Latest Information Update: 29 Jun 2023
Price :
$50
*
At a glance
- Originator Circassia
- Developer McMaster University; NIOX
- Class
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Rheumatoid-arthritis in Canada (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Rheumatoid-arthritis in United Kingdom (Parenteral)
- 30 Jul 2012 Early research in Rheumatoid arthritis in Canada (Parenteral)